Brain+
0.016
DKK
-10.34 %
Less than 1K followers
BRAINP
First North Denmark
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.
Read moreMarket cap
10.18M DKK
Turnover
41.32K DKK
Revenue
200K
EBIT %
-5,830 %
P/E
-
Dividend yield-%
-
Financial calendar
28/8
2025
Interim report Q2'25
All
Press releases
3rd party
ShowingAll content types
Invitation to investor webinar featuring Antony Hall: How new CST evidence and UK dementia care quality focus underscore the relevance and potential of Ayla
New research underscores the effects of Cognitive Stimulation Therapy, supporting its role for UK care homes to comply with care quality statements
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools